ViiV Healthcare’s berry-flavored HIV formulation will soon be available for purchase, following the FDA’s approval of Tivicay (dolutegravir) tablets for children and infants at least four weeks old in combination with other antiretrovirals.

The new formulation was announced by Unitaid, a global health initiative that has reached an agreement with generic drugmakers Viatris and Macleods to supply the drug for a yearly price of just $36 per child.

Dolutegravir belongs to a class of drugs called HIV-integrase inhibitors that reduce the amount of HIV in the blood while boosting immune-cell production.